Effects of melatonin and its analogues on pancreatic inflammation, enzyme secretion, and tumorigenesis

International Journal of Molecular Sciences

Volumn 18, Issue 5, 2017, Pages

  Jaworek, Jolanta ^a   Leja Szpak, Anna ^a   Nawrot Porąbka, Katarzyna ^a   Szklarczyk, Joanna ^a   Kot, Michalina ^a   Pierzchalski, Piotr ^a   Góralska, Marta ^a   Ceranowicz, Piotr ^a   Warzecha, Zygmunt ^a   Dembinski, Artur ^a   Bonior, Joanna ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Acute pancreatitis; AFMK; Enzyme secretion; Melatonin; Pancreatic cancer

Indexed keywords

CAPSAICIN; CHOLECYSTOKININ; FLUOROURACIL; GEMCITABINE; HEAT SHOCK PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MELATONIN; MELATONIN DERIVATIVE; MELATONIN RECEPTOR; N1 ACETYL 5 METHOXY KYNURAMINE; N1 ACETYL N1 FORMYL 5 METHOXYKYNURAMINE; NITRIC OXIDE; PANCREAS ENZYME; TARAZEPIDE; TRYPTOPHAN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ACINAR CELL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CALCIUM MOBILIZATION; CARCINOGENESIS; CEREBROSPINAL FLUID; DNA DAMAGE; ENZYME RELEASE; HUMAN; KERATINOCYTE; LIPID PEROXIDATION; MENINGITIS; NONHUMAN; OXIDATIVE STRESS; PANCREAS CANCER; PANCREAS SECRETION; PANCREATITIS; REVIEW; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; ENZYMOLOGY; METABOLISM; PANCREAS; PANCREAS TUMOR; SECRETION (PROCESS);

ANIMALS; CARCINOGENESIS; HUMANS; MELATONIN; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS; RECEPTORS, MELATONIN;

EID: 85019090899     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18051014     Document Type: Review

References (101)

1. Reiter, R.J.; Tan, D.X.; Rosales-Corral, S.; Manchester, L.C. The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives. Mini Rev. Med. Chem. 2013, 13, 373–384. [CrossRef] [PubMed]
2. Calvo, J.R.; Gonzales-Yanes, C.; Maldonado, M.D. The role of melatonin in the cells of the innate immunity: A review. J. Pineal Res. 2013, 55, 103–120. [CrossRef] [PubMed]
3. Zawilska, J.B.; Skene, D.J.; Arendt, J. Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol. Rep. 2009, 61, 383–410. [CrossRef]
4. Ren, W.; Liu, G.; Chen, S.; Yin, J.; Wang, J.; Tan, B.; Wu, G.; Bazer, F.W.; Peng, Y.; Li, T. et al. Melatonin signaling in T cells: Functions and applications. J. Pineal Res. 2017, 62. [CrossRef] [PubMed]
5. Mánka, S.; Majewska, E. Immunoregulatory action of melatonin. The mechanism of action and the effect on inflammatory cells. Postepy Hig. Med. Dosw. 2016, 70, 1059–1067. [CrossRef]
6. Chojnacki, C.; Wisniewska-Jarosińska, M.; Walecka-Kapica, E.; Klupińska, G.; Jaworek, J.; Chojnacki, J. Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. J. Physiol. Pharmacol. 2011, 62, 327–334. [PubMed]
7. Reiter, R.J.; Mayo, J.C.; Tan, D.X.; Sainz, R.M.; Alatorre-Jimenez, M.; Oin, L. Melatonin as an antioxidant: Under promises but over delivers. J. Pineal Res. 2016, 61, 253–278. [CrossRef] [PubMed]
8. Goc, Z.; Szaroma, W.; Kapusta, E.; Dziubek, K. Protective effects of melatonin on the activity of SOD, CAT, GSH-Px and GSH content in organs of mice after administration of SNP. Chin. J. Physiol. 2017, 60, 1–10. [CrossRef] [PubMed]
9. Miller, E.; Mrowicka, M.; Malinowska, K.; Kędziora, J.; Majsterek, I. The effect of whole body cryotherapy and melatonin supplementation on total antioxidative status and some antioxidative enzyme in multiple sclerosis patients. Pol. Merkur. Lek. 2011, 31, 150–153.
10. Colares, J.R.; Schemitt, E.G.; Hartmann, R.M.; Licks, F.; Soares, M.D.; Bosco, A.D.; Marroni, N.P. Antioxidant and anti-inflammatory action of melatonin in an experimental model of secondary biliary cirrosis induced by bile duct ligation. World J. Gastroenterol. 2016, 22, 8918–8928. [CrossRef] [PubMed]
11. Cutando, A.; Montero, J.; Gomez-de Diego, R.; Ferrera, M.J.; Lopez-Valverde, A. Effect of topical melatonin on serum levels of C-rective protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-α (TNFα) in patients with type 1 or type 2 diabetes and periodontal disease. J. Clin. Exp. Dent. 2015, 7, e628–e633. [PubMed]
12. Maldonado, M.D.; Garcia-Moreno, H.; Gonzales-Yanes, C.; Calvo, J.R. Possible involvement of the inhibition of NF-κB factor in anti-inflammatory actions that melatonin exerts on mast cells. J. Cell. Biochem. 2016, 117, 1926–1933. [CrossRef] [PubMed]
13. Jung, K.H.; Hong, S.W.; Zheng, H.M.; Lee, H.S.; Lee, H.; Lee, D.H.; Lee, S.Y.; Hong, S.S. Melatonin ameliorates caerulein-induced pancreatitis by the modulation of nuclear erythroid 2-related factor 2 and nuclear factor-kappa B in rats. J. Pineal Res. 2010, 48, 239–250. [CrossRef] [PubMed]
14. Chen, S.J.; Huangh, S.H.; Chen, J.W.; Wang, K.C.; Yang, Y.R.; Liu, P.F.; Lin, G.J.; Sytwu, H.K. Melatonin enhances interleukin-10 expression and suppresses chemotaxis to inhibit inflammation in situ and reduce the severity of experimental autoimmune encephalomyelitis. Int. Immunopharmacol. 2016, 32, 169–177. [CrossRef] [PubMed]
15. Huai, J.P.; Sun, X.C.; Chen, M.J.; Jin, Y.; Ye, X.H.; Wu, J.S.; Huang, Z.M. Melatonin attenuates acute pancreatitis-associated lung injury inn rats by modulating interleukin 22. World J. Gastroenterol. 2012, 18, 5122–5128. [CrossRef] [PubMed]
16. Ochoa, J.J.; Diaz-Castro, J.; Kajarabille, N.; Garcia, N.; Guisado, I.M.; De Teresa, C.; Guisado, R. Melatonin supplementation ameliorates oxidative stress and inflammatory signaling induced by strenuous exercise in adult human males. J. Pineal Res. 2011, 51, 373–380. [CrossRef] [PubMed]
17. 2+ influx activation in mouse pancreatic acinar cells. Free Radic. Biol. Med. 2015, 87, 226–236. [CrossRef] [PubMed]
18. Chen, C.Q.; Fichna, J.; Bashashati, M.; Li, Y.Y.; Storr, M. Distribution, function and physiological role of melatonin in the lower gut. World J. Gastroenterol. 2011, 17, 3888–3898. [CrossRef] [PubMed]
19. Slominski, R.M.; Reiter, R.J.; Schlabritz-Loutsevitch, N.; Ostrom, R.S.; Slominski, A.T. Melatonin membrane receptors in peripheral tissues: Distribution and functions. Mol. Cell. Endocrinol. 2012, 35, 152–166. [CrossRef] [PubMed]
20. Stebelova, K.; Anttila, K.; Manttari, S.; Saarela, S.I.; Zeman, M. Immunohistochemical definition of MT(2) receptors and melatonin in the gastrointestinal tissues of rat. Acta Histochem. 2010, 112, 26–33. [CrossRef] [PubMed]
21. Ahmed, R.; Mahavadi, S.; Al-Shboul, O.; Bhattacharya, S.; Grider, J.R.; Muthry, K.S. Characterization of signaling pathways coupled to melatonin receptors in gastrointestinal smooth muscle. Regul. Pept. 2013, 184, 96–103. [CrossRef] [PubMed]
22. Costa, E.J.; Lopes, R.H.; Lamy-Freund, M.T. Permeability of pure lipid bilayers to melatonin. J. Pineal Res. 1995, 19, 123–126. [CrossRef] [PubMed]
23. Reiter, R.J.; Tan, D.X.; Manchester, L.C.; Pilar-Terron, M.; Flores, L.J.; Koppisepi, S. Medical implications of melatonin: Receptor-mediated and receptor-independent actions. Adv. Med. Sci. 2007, 52, 11–28. [PubMed]
24. Stefulj, J.; Hortner, M.; Ghosh, M.; Schauenstein, K.; Rinner, I.; Wolfler, A.; Sonner, J.; Liebman, P.M. Gene expression of the key enzymes in melatonin synthesis in extrapineal tissues in the rat. J. Pineal Res. 2001, 30, 243–247. [CrossRef] [PubMed]
25. Shimozuma, M.; Tokuyama, R.; Tatehara, S.; Umeki, H.; Ide, S.; Mishima, K.; Saito, I.; Satomura, K. Expression and cellular localization of melatonin-synthesis enzyme in rat and human salivary glands. Histochem. Cell Biol. 2011, 135, 389–396. [CrossRef] [PubMed]
26. Jaworek, J.; Leja-Szpak, A.; Bonior, J.; Nawrot, K.; Tomaszewska, R.; Stachura, J.; Sendur, R.; Konturek, S.J. Protective effect of melatonin and its precursor L-tryptophan on acute pancreatitis induced by caerulein overstimulation or ischemia/reperfusion. J. Pineal Res. 2003, 34, 40–52. [CrossRef] [PubMed]
27. Jaworek, J.; Nawrot-Porąbka, K.; Leja-Szpak, A.; Bonior, J.; Szklarczyk, J.; Kot, M.; Konturek, S.J.; Pawlik, W.W. Melatonin as modulator of pancreatic enzyme secretion and pancreatoprotector. J. Physiol. Pharmacol. 2007, 58, 65–80. [PubMed]
28. Ciorba, M.A. Indoleamine 2,3 dioxygenase in intestinal disease. Curr. Opin. Gastroenterol. 2013, 29, 146–152. [CrossRef] [PubMed]
29. Tan, D.X.; Manchester, L.C.; Terron, M.P.; Flores, L.J.; Reiter, R.J. One molecule, many derivatives: A never-ending interaction of melatonin with the reactive oxygen and nitrogen species. J. Pineal Res. 2007, 42, 28–42. [CrossRef] [PubMed]
30. Harderland, R.; Tan, D.X.; Reiter, R.J. Kynuramines, metabolites of melatonin and other indoles: The resurrection of an almost forgotten class of biogenic amines. J. Pineal Res. 2009, 42, 109–126. [CrossRef] [PubMed]
31. 1-formyl-5-methoxy-kynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J. 2001, 15, 2294–2296. [PubMed]
32. Janjetovic, Z.; Nahmias, Z.P.; Hanna, S.; Jarrett, S.G.; Kim, T.K.; Reiter, R.J.; Slominski, A.T. Melatonin and its metabolites ameliorate ultraviolet B-induced damage in human epidermal keratinocytes. J. Pineal Res. 2014, 57, 90–102. [CrossRef] [PubMed]
33. 1-formyl-5-methoxy- kynuramine is a potent singlet oxygen scavenger. J. Pineal Res. 2009, 46, 49–52. [CrossRef] [PubMed]
34. 1-formyl-5-methoxykynuramine (AFMK), and N1-acetyl-5-methoxykynuramine (AMK) in macrophages. J. Neuroimmunol. 2005, 165, 139–149. [CrossRef] [PubMed]
35. Galano, A.; Tan, X.; Reiter, R.J. On the free radical scavenging activities of melatonin’s metabolites, AFMK and AMK. J. Pineal Res. 2013, 54, 245–257. [CrossRef] [PubMed]
36. Silva, S.O.; Ximenez, V.F.; Livramento, J.A.; Catalani, L.H.; Campa, A. High concentration of melatonin metabolite N1-acety-N1formyl-5-methoxykynuramine in cerebrospinal fluid of patients with meningitis; a possible immunomodulatory mechanism. J. Pineal Res. 2005, 39, 302–306. [CrossRef] [PubMed]
37. Acuna-Castroviejo, D.; Escames, G.; Vernegas, C.; Diaz-Casado, M.E.; Lima-Cabello, E.; Lopez, L.C.; Rosales-Corral, S.; Tan, D.X.; Reiter, R.J. Extrapineal melatonin: Sources, regulation and potential functions. Cell Mol. Life Sci. 2014, 71, 2997–3025. [CrossRef] [PubMed]
38. Hardeland, R.; Poeggeler, B. Melatonin and synthetic melatonergic agonists: Actions and metabolism in the central nervous system. Cent. Nerv. Syst. Agents Med. Chem. 2012, 12, 189–216. [CrossRef] [PubMed]
39. Bubenik, G.A. Localization, physiological significance and possible clinical implication of gastrointestinal melatonin. Biol. Signals Recept. 2001, 10, 350–366. [CrossRef] [PubMed]
40. Soderquist, F.; Hellstrom, P.M.; Cunningham, J.L. Human gastroenteropancreatic expression of melatonin and its receptors MT1 and MT2. PLoS ONE 2015, 10, e0120195. [CrossRef] [PubMed]
41. Bubenik, G.A.; Brown, G.M. Pinealectomy reduces melatonin levels in the serum but not in the gastrointestinal tract of the rat. Biol. Signals 1997, 6, 40–44. [CrossRef] [PubMed]
42. Peschke, E.; Bahr, I.; Muhlbauer, E. Melatonin and pancreatic islets: Interrelationships between melatonin, insulin and glucagon. Int. J. Mol. Sci. 2013, 14, 6981–7015. [CrossRef] [PubMed]
43. Leja-Szpak, A.; Jaworek, J.; Pierzchalski, P.; Reiter, R.J. Melatonin Induces Pro-apoptotic Signaling Pathway in Human Pancreatic Carcinoma Cells (PANC-1). J. Pineal Res. 2010, 49, 248–255. [CrossRef] [PubMed]
44. Gonzales, A.; del Castillo-Vaquero, A.; Miro-Moran, A.; Tapia, J.A.; Salido, G.M. Melatonin reduces pancreatic tumor cell viability by altering mitochondrial physiology. J. Pineal Res. 2011, 50, 250–260. [CrossRef] [PubMed]
45. Jaworek, J.; Nawrot-Porabka, K.; Konturek, S.J.; Leja-Szpak, A.; Thor, P.; Pawlik, W.W. Melatonin and its precursor L-tryptophan: Influence on pancreatic amylase secretion in vivo and in vitro. J. Pineal Res. 2004, 36, 155–164. [CrossRef] [PubMed]
46. Leja-Szpak, A.; Jaworek, J.; Nawrot-Porabka, K.; Palonek, M.; Mitis-Musiol, M.; Dembinski, A.; Konturek, S.J.; Pawlik, W.W. Modulation of pancreatic enzyme secretion by melatonin and its precursor: L-tryptophan. Role of CCK and afferent nerves. J. Physiol. Pharmacol. 2004, 55, 33–46. [PubMed]
47. 2+ mobilization and amylase release in response to cholecystokinin octapeptide in mouse pancreatic acinar cells. J. Physiol. Biochem. 2013, 69, 897–908. [CrossRef] [PubMed]
48. Bernard, P.P.; Polglaze, K.E.; Bernard, R.L.; Sandow, S.L.; Pozo, M.J. Detection of melatonin production from the intestinal epithelium using electochemical method. Curr. Pharm. Des. 2014, 20, 4802–4806.
49. Hardeland, R. Melatonin in plants-diversity of levels and multiplicity of functions. Front. Plant Sci. 2016, 7, 198. [CrossRef] [PubMed]
50. Bharwani, N.; Patel, S.; Prabhudesai, S.; Fotheringham, T.; Power, N. Acute pancreatitis: The role of imagining in diagnosis and management. Clin. Radiol. 2011, 66, 164–175. [CrossRef] [PubMed]
51. Gurusamy, K.S.; Belgaumkatr, A.P.; Haswell, A.; Pereira, S.P.; Davidson, B.R. Interventions for necrotizing pancreatitis. Cochrane Database Syst. Rev. 2016, 4, CD011383. [PubMed]
52. Singh, P.; Garg, P.K. Pathophysiological mechanisms in acute pancreatitis: Current understanding. Indian J. Gastroenterol. 2016, 35, 153–166. [CrossRef] [PubMed]
53. Sah, R.P.; Dawra, R.K.; Saluja, A.K. New insights into the pathogenesis in pancreatitis. Curr. Opin. Gastroenterol. 2013, 29, 523–530. [CrossRef] [PubMed]
54. Manohar, M.; Verma, A.K.; Venkateshaiah, S.U.; Sanders, N.L.; Mishra, A. Pathogenetic mechanism of pancreatitis. World J. Gastrointest. Pharmacol. Ther. 2017, 8, 10–25. [CrossRef] [PubMed]
55. Mylona, V.; Koussoulas, V.; Tzivras, D.; Makrygiannis, E.; Georgopoulou, P.; Koratzanis, G.; Giamarellos-Bourboulis, E.J.; Tzivras, M.D. Changes in adaptative and innate immunity in patients with acute pancreatitis and systemic inflammatory response syndrome. Pancreatology 2011, 11, 475–481. [CrossRef] [PubMed]
56. Bhatia, M. Acute pancreatitis as a model of SIRS. Front. Biosci. 2009, 14, 2042–2050. [CrossRef]
57. Duan, L.; Ma, Y.; Chi, J.; Wang, X.; Wesely, A.J.; Chen, X. The regulatory role of immunosupressants on immune abnormalities in acute pancreatitis. Biomed. Rep. 2014, 2, 193–198. [PubMed]
58. Watanabe, T.; Kudo, M.; Strober, W. Immunopathogenesis of pancreatitis. Mucosal Immunol. 2017, 10, 283–298. [CrossRef] [PubMed]
59. Jaworek, J.; Konturek, S.J. Hormonal protection in acute pancreatitis by ghrelin, leptin and melatonin. World J. Gastroenterol. 2014, 20, 16902–16912. [CrossRef] [PubMed]
60. Szabolcs, A.; Reiter, R.J.; Letoha, T.; Hegy, P.; Papai, G.; Varga, I.; Jarmay, K.; Kaszaki, J.; Sari, R.; Rakonczay, Z. Jr.. et al. Effect of melatonin on the severity of L-arginine-induced experimental pancreatitis in rats. World J. Gastroenterol. 2006, 12, 251–258. [CrossRef] [PubMed]
61. Jaworek, J. Ghrelin and melatonin in the regulation of pancreatic exocrine secretion and maintaining of integrity. J. Physiol. Pharmacol. 2006, 57, 83–96. [PubMed]
62. Qi, W.; Tan, R.X.; Reiter, R.J. Melatonin reduces lipid peroxidation and tissue edema in caerulein-induced acute pancreatitis in the rats. Dig. Dis. Sci. 1999, 44, 2257–2262. [CrossRef] [PubMed]
63. Jaworek, J.; Konturek, S.J.; Leja-Szpak, A. Role of endogenous melatonin and its MT2 receptor in the modulation of caerulein-induced pancreatitis in the rat. J. Physiol. Pharmacol. 2002, 53, 791–804. [PubMed]
64. Esrefoglu, M.; Gul, M.; Ates, B.; Selimoglu, M.A. Ultrastructural clues for the protective effect of melatonin against oxidative damage in cerulein-induced pancreatitis. J. Pineal Res. 2006, 40, 92–97. [CrossRef] [PubMed]
65. Carrasco, C.; Marchena, A.M.; Holquin-Arevalo, M.S.; Martin-Partido, G.; Rodriquez, A.B.; Paredes, S.D.; Pariente, J.A. Anti-inflammatory effect of melatonin in a rat model of caerulein-induced acute pancreatitis. Cell Biochem. Funct. 2013, 31, 585–590. [CrossRef] [PubMed]
66. Chen, H.M.; Chen, J.C.; Ng, C.J.; Chiu, D.F.; Chen, M.F. Melatonin reduces pancreatic prostaglandins production and protects against caerulein-induced pancreatitis. J. Pineal Res. 2006, 40, 34–39. [CrossRef] [PubMed]
67. Jaworek, J.; Konturek, S.J.; Tomaszewska, R.; Leja-Szpak, A.; Bonior, J.; Nawrot, K.; Palonek, M.; Stachura, J.; Pawlik, W. The circadian rhythm of melatonin modulates the severity of caerulein-induced pancreatitis in the rat. J. Pineal Res. 2004, 37, 161–170. [CrossRef] [PubMed]
68. Col, C.; Dinler, K.; Hasdemir, A.O.; Bugdayci, G. The effect of intraperitoneal injection of melatonin on serum amylase levels in acute pancreatitis. JOP 2009, 10, 306–309. [PubMed]
69. Baykal, A.; Iskit, A.B.; Hamaloglou, E.; Oguz, M.; Hascelik, G.; Sayek, Y. Melatonin modulates mesenteric blood flow and TNF alpha concentrations after lipopolysaccharide challenge. Eur. J. Surg. 2000, 166, 722–727. [PubMed]
70. Sadek, A.S.; Khattab, R.S. The protective role of melatonin on L-arginine-induced acute pancreatitis. Folia Morphol. 2017, 76, 66–73. [CrossRef] [PubMed]
71. Huai, J.P.; Shao, Y.; Sun, X.C.; Jin, Y.; Wu, J.S.; Huang, Z.M. Melatonin ameliorates necrotizing pancreatitis by the regulation of cytosolic Ca+2 homeostasis. Pancreatology 2012, 12, 257–263. [CrossRef] [PubMed]
72. Chen, Y.; Zhang, J.; Zhao, Q.; Chen, Q.W.; Sun, Y.; Jin, Y.; Wu, J. Melatonin induces anti-inflammatory effects to play a protective role via endoplasmatic reticulum stress in acute pancreatitis. Cell. Physiol. Biochem. 2016, 40, 1094–1104. [CrossRef] [PubMed]
73. Gulben, K.; Ozdemir, H.; Berberoglu, U.; Mersin, H.; Yrkin, F.; Cahyr, E.; Aksaray, S. Melatonin modulates the severity of taurocholate-induced acute pancreatitis. Dig. Dis. Sci. 2010, 55, 941–946. [CrossRef] [PubMed]
74. Bonior, J.; Jaworek, J.; Konturek, S.J.; Pawlik, W.W. Increase of heat shock protein gene expression by melatonin in AR42J cells. J. Physiol. Pharmacol. 2005, 56, 471–481. [PubMed]
75. Sun, X.; Shao, Y.; Jin, Y.; Huai, J.; Zhou, Q.; Huang, Z.; Wu, J. Melatonin reduces bacterial translocation by preventing damage to the intestinal mucosa in an experimental severe pancreatitis rat model. Exp. Ther. Med. 2013, 6, 1343–1349. [PubMed]
76. Chou, T.Y.; Reiter, R.J.; Chen, K.H.; Leu, F.J.; Wang, D.; Yeh, D.Y. Pulmonary function changes in rats with taurocholate-induced pancreatitis are attenuated by pretreatment with melatonin. J. Pineal Res. 2014, 56, 196–203. [CrossRef] [PubMed]
77. Sidhu, S.; Pandhi, P.; Malhortra, S.; Vaiphei, K.; Khanduya, K.L. Melatonin treatment is beneficial in pancreatic repair process after experimental acute pancreatitis. Eur. J. Pharmacol. 2010, 628, 282–289. [CrossRef] [PubMed]
78. 1-formyl-5nmethoxykynuramine (AFMK), attenuates acute pancreatitis in the rat: In vivo and in vitro studies. J. Physiol. Pharmacol. 2016, 676, 411–421.
79. Chen, G.Y.; Dai, R.W.; Luo, H.; Chen, T.; Lin, N.; Wang, T.; Luo, G.D.; Tang, L.J. Effect of percutaneous catheter drainage on pancreatic injury in rats with severe acute pancreatitis induced by sodium taurocholate. Pancreatology 2015, 15, 71–77. [CrossRef] [PubMed]
80. Booth, D.M.; Murphy, J.A.; Mukherjee, R.; Awais, M.; Neoptolemos, J.P.; Gerasimenko, O.V.; Tepikin, A.V.; Petersen, O.H.; Sutton, R.; Criddle, D.N. Reactive oxygen species induced by bile acid induce apoptosis and protect against necrosis in pancreatic acinar cells. Gastroenterology 2011, 140, 2116–2125. [CrossRef] [PubMed]
81. Laothong, U.; Hiraku, Y.; Oikawa, S.; Intuyod, K.; Murata, M.; Pinlaor, S. Melatonin induces apoptosis in cholangiocarcinoma cell lines by activating the reactive oxygen species-mediated mitochondrial pathway. Oncol. Rep. 2015, 33, 1443–1449. [CrossRef] [PubMed]
82. Xu, C.; Wu, A.; Zhu, H.; Fang, H.; Xu, L.; Ye, J.; Shen, J. Melatonin is involved in the apoptosis and necrosis of pancreatic cancer cell line via modulating of Bcl-2/Bax balance. Biomed. Pharmacother. 2013, 67, 133–139. [CrossRef] [PubMed]
83. Wei, J.Y.; Li, M.W.; Zhou, L.L.; Lu, Q.N.; He, W. Melatonin induced apoptosis of colorectal cancer cells through HDAC4 nuclear import mediated by CaMKII inactivation. J. Pineal Res. 2015, 58, 429–438. [CrossRef] [PubMed]
84. Jaworek, J.; Zwirska-Korczala, K.; Szklarczyk, J.; Nawrot-Porąbka, K.; Leja-Szpak, A.; Jaworek, A.K.; Tomaszewska, R. Pinealectomy aggravates acute pancreatitis in the rat. Pharmacol. Rev. 2010, 62, 864–873. [CrossRef]
85. Belayev, O.; Herzog, T.; Munding, J.; Bolik, B.; Vosschulte, A.; Uhl, W.; Muller, C.A. Protective role of endogenous melatonin in the early course of human acute pancreatitis. J. Pineal Res. 2011, 50, 71–77. [CrossRef] [PubMed]
86. Jin, Y.; Lin, C.J.; Dong, L.M.; Chen, M.J.; Zhou, Q.; Wu, J.S. Clinical significance of melatonin concentrations in predicting the severity of acute pancreatitis. World J. Gastroenterol. 2013, 19, 4066–4071. [CrossRef] [PubMed]
87. Leja-Szpak, A.; Jaworek, J.; Szklarczyk, J.; Konturek, S.J.; Pawlik, W.W. Melatonin stimulates HSP27 phosphorylation in human pancreatic carcinoma cells (PANC-1). J. Physiol. Pharmacol. 2007, 58, 177–188. [PubMed]
88. Jaworek, J.; Leja-Szpak, A. Melatonin influences pancreatic cancerogenesis. Histol. Histopathol. 2014, 29, 423–431. [PubMed]
89. Li, W.; Wu, J.; Li, Z.; Zhou, Z.; Zheng, C.; Lin, L.; Tan, B.; Huang, M.; Fan, M. Melatonin induces cell apoptosis in Mia PaCa-2 cells via the suppression of nuclear factor-κB and activation of ERK and JNK: A novel therapeutic implication for pancreatic cancer. Oncol. Rep. 2016, 36, 2861–2867. [CrossRef] [PubMed]
90. Cucina, A.; Proietti, S.; D’Anselmi, F.; Coluccia, P.; Dinicola, S.; Frati, L.; Bizzarri, M. Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells. J. Pineal Res. 2009, 46, 172–180. [CrossRef] [PubMed]
91. Fan, C.; Pan, Y.; Yang, Y.; Di, S.; Jiang, S.; Ma, Z.; Li, T.; Zhang, Z.; Li, W.; Li, X. et al. HDAC1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways. J. Pineal Res. 2015, 59, 321–333. [CrossRef] [PubMed]
92. Hong, Y.; Won, J.; Lee, Y.; Lee, S.; Park, K.; Chang, K.T.; Hong, Y. Melatonin treatment induces interplay of apoptosis, autophagy, and senescence in human colorectal cancer cells. J. Pineal Res. 2014, 56, 264–274. [CrossRef] [PubMed]
93. Kim, T.K.; Lin, Z.; Tidwell, W.J.; Li, W.; Slominski, A.T. Melatonin and its metabolites accumulate in the human epidermis in vivo and inhibit proliferation and tyrosinase activity in epidermal melanocytes in vitro. Mol. Cell. Endocrinol. 2015, 404, 1–8. [CrossRef] [PubMed]
94. Leja-Szpak, A.; Pierzchalski, P.; Goralska, M.; Nawrot-Porabka, K.; Bonior, J.; Link-Lenczowski, P.; Jastrzebska, M.; Jaworek, J. Kynuramines induce overexpression of heat shock proteins in pancreatic cancer cells via 5-hydroxytryptamine and MT1/MT2 receptors. J. Physiol. Pharmacol. 2015, 66, 711–718. [PubMed]
95. 2-formyl-5-methoxykynuramine is a product of melatonin oxidation in rats. J. Pineal Res. 2003, 35, 245–250. [CrossRef] [PubMed]
96. 2-formyl-5-methoxykynuramine, quercetin or resveratrol. J. Pineal Res. 2005, 38, 107–115. [CrossRef] [PubMed]
97. Boutin, J.A.; Marcheteau, E.; Hennig, P.; Moulharat, N.; Berger, S.; Delagrange, P.; Bouchet, J.P.; Ferry, G. MT3/QR2 melatonin binding site does not use melatonin as a substrate or a co-substrate. J. Pineal Res. 2008, 45, 524–531. [CrossRef] [PubMed]
98. 2-formyl-5-methoxykynuramine modulates the cell cycle of malaria parasites. J. Pineal Res. 2007, 42, 261–266. [CrossRef] [PubMed]
99. Dragicevic, N.; Copes, N.; O’Neal-Moffitt, G.; Jin, J.; Buzzeo, R.; Mamcarz, M.; Tan, J.; Cao, C.; Olcese, J.M.; Arendash, G.W. et al. Melatonin treatment restores mitochondrial function in Alzheimer’s mice: A mitochondrial protective role of melatonin membrane receptor signaling. J. Pineal Res. 2011, 51, 75–86. [CrossRef] [PubMed]
100. Ju, HQ.; Li, H.; Tian, T.; Lu, Y.X.; Bai, L.; Chen, L.Z.; Sheng, H.; Mo, H.Y.; Zeng, J.B.; Deng, W. et al. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation. J. Pineal Res. 2016, 60, 27–38. [CrossRef] [PubMed]
101. Uguz, A.C.; Cig, B.; Espino, J.; Bejarano, I.; Naziroglu, M.; Rodríguez, A.B.; Pariente, J.A. Melatonin potentiates chemotherapy-induced cytotoxicity and apoptosis in rat pancreatic tumor cells. J. Pineal Res. 2012, 53, 91–98. [CrossRef] [PubMed]